GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Pre-Tax Income

Nabriva Therapeutics (Nabriva Therapeutics) Pre-Tax Income

: $-54.23 Mil (TTM As of Jun. 2023)
View and export this data going back to 2017. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Nabriva Therapeutics's pretax income for the three months ended in Jun. 2023 was $-12.06 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was $-54.23 Mil. Nabriva Therapeutics's pretax margin was -468.61%.

During the past 10 years, Nabriva Therapeutics's highest Pretax Margin was -155.93%. The lowest was -2421.26%. And the median was -1066.89%.


Nabriva Therapeutics Pre-Tax Income Historical Data

The historical data trend for Nabriva Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pre-Tax Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.73 -82.66 -69.35 -48.96 -55.62

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Pre-Tax Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.69 -10.99 -22.47 -8.70 -12.06

Competitive Comparison

For the Biotechnology subindustry, Nabriva Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nabriva Therapeutics Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Pre-Tax Income falls into.



Nabriva Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nabriva Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-51.173+-3.746+-0.698+0+7.105427357601E-15
=-55.62

Nabriva Therapeutics's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-12.024+-0.039+0+0+0.00099999999999945
=-12.06

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nabriva Therapeutics  (OTCPK:NBRVF) Pre-Tax Income Explanation

Nabriva Therapeutics's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-12.062/2.574
=-468.61%

During the past 10 years, Nabriva Therapeutics's highest Pretax Margin was -155.93%. The lowest was -2421.26%. And the median was -1066.89%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nabriva Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Executives
Hogan H Michael Iii officer: Chief Executive Officer C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio officer: Chief Financial Officer 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan director
Broom Colin Md officer: Chief Executive Officer 119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow officer: Director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder officer: Chief Executive Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger officer: General Counsel and Corp Sec 633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia officer: Chief Medical Officer C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan officer: Chief Financial Officer C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino officer: Chief Commercial Officer 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty officer: General Counsel & Corp Sec. 1301 2ND AVE, SEATTLE WA 98101

Nabriva Therapeutics (Nabriva Therapeutics) Headlines

From GuruFocus